AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06410443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics, probiotics, vitamins, antidiarrheal drugs, enteral nutrition, and endoscopic argon plasma coagulation
Description: Treatment according to guideline of radiation-induced intestinal injury.
Study NCT04994132 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT04994132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT04994132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine Tartrate
Description: Given IV
Study NCT04994132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray imaging
Study NCT05876650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercises
Description: Pilates exercises starts with warm up, followed by 6 main exercises that are Swan, Swimming, Prone press up, Dart, Arm arch and Scarecow. The session will end with the cool down exercises. Each exercise will be repeated 10 times for 5 sets. Patients will be treated 3 times per week for 4 consecutive weeks.
Study NCT05876650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga will start with warm up followed by 6 yoga poses which are Warrior pose 1, Triangle pose, Child pose, Cow face pose, Bound angle pose, half bow poseThe session will end with a cool down pose. Each yoga pose will be held for 8-10 breathes Patients will be treated 3 times per week for 4 consecutive weeks.
Study NCT05521997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaglenastat
Description: -800 mg twice per day by mouth
Study NCT05521997 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation treatment
Description: * Standard of care~* External beam radiation therapy delivered daily 4 days a week and 1 day per week of brachytherapy.
Study NCT05521997 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation treatment
Description: * Standard of care~* External beam radiation therapy delivered daily 4 days a week and 1 day per week of brachytherapy.
Study NCT05521997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: * Standard of care~* Weekly administration of cisplain
Study NCT05521997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: * Standard of care~* Weekly administration of cisplain
Study NCT04982432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orismilast
Description: Orismilast is a next generation PD4 inhibitor with demonstrated broad anti inflammatory properties
Study NCT06305247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPN01194
Description: IPN01194 will be taken orally over a period of 28 days (a Cycle) at the assigned dose level. The dose limiting toxicity (DLT) observation period consists of the first 28 days of treatment with IPN01194 (Cycle 1).~Participants will receive IPN01194 treatment beyond Cycle 1 until treatment is precluded by toxicity, disease progression, or upon participant's request or investigator decision.
Study NCT06305247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPN01194
Description: All participants will receive IPN01194 orally for 28-day cycles at one of the two dose levels determined at the end of Phase I.~Participants will receive IPN01194 treatment until treatment is precluded by toxicity, disease progression, or upon participant's request or investigator decision
Study NCT04795713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-6402
Description: Experimental Treatment
Study NCT05428696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Powder-in-capsule
Study NCT04473326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinforcement Learning
Description: Participants in the intervention arm will receive up to daily, tailored text messages based on their electronic pill bottle-measured adherence. Given the participants' baseline characteristics and time-varying responses to the messages, a reinforcement learning algorithm will deliver different text messages and adapt over time to determine which type of messaging works best for each individual participant.
Study NCT05394272 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Therapy - Pranic Healing
Description: Energy therapy - Non invasive non touch and non pharmacological - 100% natural complementary therapy
Study NCT05475379 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Typhoid Vi polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT)
Description: Typhoid Vi-polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT) Typhocon will be manufactured by Incepta Vaccine Limited
Study NCT05475379 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typhoid Vi polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT)
Description: Typhoid Vi-polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT) Typhocon will be manufactured by Incepta Vaccine Limited
Study NCT05646797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2074
Description: intravenous (IV) infusion
Study NCT05280080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: Do the maximum number of repetitions of externally-resisted (50% 1RM) knee extensions.
Study NCT05280080 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance exercise
Description: Do the maximum number of repetitions of externally-resisted (50% 1RM) knee extensions.
Study NCT05193734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertagen®
Description: Schedule:~Group Pertagen will receive two doses of Pertagen®. (one vaccination on Day 0 and 6 months later for each volunteer.)~Mode of Administration:~Intramuscular injection into the deltoid region of the upper extremity, using a syringe with a 1 to 1.5 inch #25-gauge sterile needle.
Study NCT05193734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Revaxis®
Description: Schedule:~Group Control will receive one dose of Revaxis® on Day 0 followed by 1 dose of Pertagen® 6 months later for each volunteer.~Mode of Administration:~Intramuscular injection into the deltoid region of the upper extremity, using a syringe with a 1 to 1.5 inch #25-gauge sterile needle.
Study NCT06103383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Controlled ovarian stimuation
Description: 3 days stimullation protocol using hMG-HP
Study NCT06103383 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oocyte pick up
Description: Surgical oocyte pick up without triggering
Study NCT06103383 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oocyte in vitro maturation
Description: In vitro maturation procedure
Study NCT06103383 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oocyte in vitro activation
Description: In vitro oocyte activation procedure
Study NCT05435534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ActiveFLS intervention
Description: * A comprehensive geriatric assessment with a multicomponent physical exercise program guideline based on ActiveHip+ for 3 months. In the subsequent revisions, exercise guidelines from the Vivifrail program will be given~* A protocolized nutritional intervention will be carried out. In case of oral nutritional supplementation, supplements enriched in β-hydroxy-β-methylbutyrate (HMB) will be selected~* Osteoporosis treatments according to national guideline~* A review and adaptation of the treatment will be carried out according to the STOPP (Screening Tool of Older Persons' Prescriptions) and START (Screening Tool to Alert to Right Treatment) criteria~* An approach will be made to the patient's mood and fear of falling. In case of depression, both pharmacological and non-pharmacological approaches will be assessed~* Screening for cognitive impairment will be performed. In the event of evidence of memory problems, a recommendations for cognitive stimulation will be delivered
Study NCT05435534 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care group
Description: Participants randomly assigned to the usual care group will receive normal outpatient care, including physical rehabilitation when needed.
Study NCT06228196 — intervention group
Intervention type: DEVICE
Intervention: Simultaneous cortico-spinal magnetic resonance imaging, Serum
Description: Simultaneous cortico-spinal magnetic resonance imaging data were collected in a strong magnetic field and collected the serum of participants.
Study NCT06548620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD06-04 cell infusion
Description: CAR T Cells
Study NCT05982171 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exo + TSCS
Description: Participants will receive TSCS delivered with the ONWARD Lift system at 1ms using a 10kHz carrier frequency delivered at 30Hz, with an amplitude set for each participant based on their ability to increase voluntary movement output.
Study NCT05982171 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Exo + Sham
Description: The ONWARD Lift system will also be used to deliver sham stimulation which will also be delivered at 1ms using a 10kHz carrier frequency delivered at 30Hz, and an amplitude of 1ma which has been used in other sham stimulation protocols and is not sufficient to induce activation of lumbosacral neuronal pools.
Study NCT04967950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 MG
Description: Secukinumab 150 mg s.c. with loading dose at baseline, week 1,2,3,4 and then every 4 weeks from week 5 up to 12 weeks. After which, if MASEI ultrasound enthesitis score improvement is less than 50%, Secukinumab 150 mg will be with a switch to 300 mg.
Study NCT04967950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 MG
Description: Methotrexate 15 mg po. every week up to 12 weeks. After which, if MASEI ultrasound enthesitis score improvement is less than 50%, methotrexate with a switch to Secukinumab 150 mg at 12 weeks.
Study NCT04967950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: methotrexate
Study NCT05877599 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous, engineered T Cells targeting TP53 R175H
Description: * Pre-conditioning by non-myeloablative chemotherapy with fludarabine and cyclophosphamide~* Single infusion TCR T cells~* Post-infusion recombinant interleukin-2 (rIL-2)
Study NCT05091203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: To investigate role of vitamin D in follicular maturation and number of mature follicles which help in the success of IVF procedure
Study NCT05091203 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Vitamin D
Description: To investigate role of vitamin D in follicular maturation and number of mature follicles which help in the success of IVF procedure
Study NCT06653023 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Universal CAR-T cells injection for treating HCC and NSCLC
Description: A novel universal CAR-T platform to treat cancer patients
Study NCT06512467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: 200 mg BID,oral administration will start before the first HAIC treatment .
Study NCT06512467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200 mg Q3W,Intravenous infusion will perform before HAIC treatment.
Study NCT06512467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HAIC
Description: HAIC,Q3W. The total number of HAIC treatments was determined by the investigator based on patient needs. Dose: Oxaliplatin 85 mg / m2 for 2h, Calcium folinate 400 mg / m2 for 2h, 5-FU 400 mg / m2 for 10min, followed by 5-FU 1200 mg / m2 for 23 hours).
Study NCT05809011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: After enrollment and randomization, the intervention (experimental arm) will be the administration of corticosteroid therapy, added to standard therapy for acute heart failure. Corticosteroid therapy will be administered as a single-bolus intravenous injection of dexamethasone 20 mg (day 1, as soon as possible after randomization), followed by oral prednisone 1 mg/kg daily (maximum 60 mg daily) from day 2 to day 7 after randomization, administered at about 8.00 AM.
Study NCT05809011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: After enrollment and randomization, the intervention (experimental arm) will be the administration of corticosteroid therapy, added to standard therapy for acute heart failure. Corticosteroid therapy will be administered as a single-bolus intravenous injection of dexamethasone 20 mg (day 1, as soon as possible after randomization), followed by oral prednisone 1 mg/kg daily (maximum 60 mg daily) from day 2 to day 7 after randomization, administered at about 8.00 AM.
Study NCT04961801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib, tacrolimus, methotrexate
Description: For Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia
Study NCT06536985 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: treatment group
Description: Researchers will collaborate with participants to develop personalized intervention plans, which include physical exercise, oral function training, basic dietary guidance, and detailed oral health knowledge directly related to oral health behaviors. To facilitate better communication and management, a WeChat group will be created to encourage participants to share their daily exercise achievements. In the first week, face-to-face oral function training sessions will be organized for the intervention group at the nursing home activity center. Concurrently, once a week, the intervention group will gather at the nursing home activity center to practice together using illustrated videos. On Wednesdays, educational articles and videos about oral health are sent via text message. On Fridays, a group communication activity is organized to enhance their social connections. Additionally, we will guide elderly participants to master essential internet skills, enabling them to use smartphones to
Study NCT06536985 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contral group
Description: Participants in the control group will receive general lifestyle advice via text message once or twice a week.They will not participate in the intervention\&#39;s fitness routines, online classes, group chats, or films with health educators. Individual workout regimens, goals, or comments are not given by researchers. Participants in the control group\&#39;s complaints or questions will always be answered with basic health information and suggestions. Researchers won\&#39;t ask for individual advice or comments from other professionals.
Study NCT04855721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUR101
Description: Oral ROR-gamma inverse agonist
Study NCT05900349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate mouth rinsing
Description: the carbohydrate solution was prepared by dissolving 6.4 g of colorless and odorless maltodextrin in 93.6 mL of water; the mixtures were then adjusted to a 6.4% maltodextrin solution for the participants to rinse their mouths for 20 seconds
Study NCT05900349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine gum
Description: Chewing caffeinated gum for 20 minutes
Study NCT06549322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The exercise in morning
Description: Resistance exercises are in the following order: squat, bench press, deadlift. Each exercise consists of 3 sets with 7 repetitions, using a load of 70% 1RM with 60 sec of rest between sets.~Exercise timing: AM 11:00-11:30
Study NCT06549322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The exercise in evening
Description: Resistance exercises are in the following order: squat, bench press, deadlift. Each exercise consists of 3 sets with 7 repetitions, using a load of 70% 1RM with 60 sec of rest between sets.~Exercise timing: PM 05:00-05:30
Study NCT04494737 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Program 1
Description: A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
Study NCT04494737 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Program 2
Description: A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
Study NCT05095441 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C5252
Description: A single dose of C5252 will be administered up to 2mL as intratumoral injection on Day 1.
Study NCT04576780 — intervention group
Intervention type: OTHER
Intervention: Integrated Large Complex Polyp Referral Pathway
Description: The referring doctor will use a standardized template to send the referral along with its associated video or high-resolution photographs.~Referrals will be reviewed in a consensus fashion by at least 2 expert physicians at St. Michael's Hospital (SMH) on a bi-weekly basis. Polyps will be scored using a standardized evaluation form that documents relevant polyp features to assist the determination of whether a lesion is amenable to curative endoscopic resection.~Cases will be triaged as being: (1) a standard polyp suitable for local removal in the community; (2) a complex polyp requiring expert removal at SMH with priority assigned based on the suspected risk of invasive disease; (3) a polyp that is not amenable to endoscopic resection or that is suspicious for cancer will that be recommended for surgical resection.
Study NCT06176456 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Active regiment
Study NCT06176456 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tactile artefacts without magnetic pulses
Study NCT05729815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation
Description: Sessions focused on relaxations activities (Jacques Choque Method).
Study NCT05729815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Loose parts play
Description: Loose parts play-based sessions, with open-ended materials.
Study NCT05729815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined
Description: Sessions focused on loose parts play and relaxation activities.
Study NCT06186505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirGlove
Description: AirGlove is a unique warming system developed to enable access to the veins in a patients arm for the delivery of intraveneous drugs by gently heating the patients arm up as it forces warm air through a double walled polythene glove. In this study, the device will be used on the leg of the participants as means of encouraging circulation to the area.
Study NCT05397977 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mechanical traction group
Description: In the mechanical traction group, 26 people with cervicogenic headache will be traction with the Chattanooga Tru Trac traction device, 6 days a week for 2 weeks.~Persons to be mechanically traction will be placed on their backs on the treatment bed with their necks on the neck collar of the device. After the patients are fixed to the head, the pulling force of the device will start with 10% of the patient's body weight, the device will be set as 60 seconds of pulling force and 20 seconds of relaxation. In subsequent sessions, the pulling force will be gradually adjusted based on the patient's previous traction therapy, tolerance, and symptom response. Each session will take 15 minutes.~Participants will be given 20 minutes of TENS, 20 minutes of hotpack and 4 minutes of ultrasound, and the exercise will be given as a home program.
Study NCT05397977 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manuel traction group
Description: Manual traction, one of Cyriax's neck mobilization techniques, will be applied to the MTG. Vertebrobasilar artery test will be applied to the patients before starting the treatment, and manual traction will be applied to the patients in case the vertebrobasilar artery test is negative. Manual traction technique will be applied to the cervical region for 15 minutes. While applying manual traction, the patient will be placed on his back with his head hanging off the bed. Grasp the occiput with one hand and under the chin with the other. Manual traction will be applied by keeping the neck neutral and the occiput slightly extended. After applying traction for a few seconds, it will be slowly released and returned to the starting position, and the application will be made for 15 minutes.~20 minutes of TENS, 20 minutes of hotpack and 4 minutes of ultrasound will be applied to the participants, and the exercise will be given as a home program.
Study NCT05241314 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learning to BREATHE
Description: A 6 session group-based intervention targeting adolescent mindfulness. The adapted and merged intervention will be delivered to individual families (home-based) in twice-weekly sessions over a 7-week period by two community health worker interventionists.
Study NCT05235464 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard meal
Description: Standard meal
Study NCT05235464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High animal protein meal
Description: Meal with high animal protein content
Study NCT05235464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High plant protein meal
Description: Meal with high plant protein content
Study NCT05235464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High plant protein meal with additional leucine
Description: Meal with high plant protein content and additional leucine